Amarin Sets the Record Straight on Sarissa’s Latest Misstatements

DUBLIN, IRELAND and BRIDGEWATER. NJ, February 27, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today released the following statement in response to Sarissa’s recent misstatements regarding the Company’s executive compensation:

Consistent with standard practice of public companies and consistent with its fiduciary duties, Amarin’s board of directors approved its 2023 management compensation plan. Contrary to Sarissa’s claims, the timing of plan approval was in February, consistent with previous years. In addition, as part of this year’s Compensation Plan (as in all previous years), all Amarin employees worldwide received annual performance grants. Sarissa’s comment that Karim Mikhail’s stock awards vest “solely on the basis of the passage of time” is also another misrepresentation of the facts. Mr. Mikhail’s compensation package includes performance-based grants that are triggered only when performance thresholds are met.

Sarissa also insinuates that the board “refuses” to publish the results of the AGM – another misrepresentation of the facts. The AGM has not yet taken place, and both Sarissa and her legal counsel know that under SEC guidelines, companies do not release preliminary results before a general meeting. The Board of Directors assures the shareholders that the results of the general meeting will be published shortly after the end of the meeting.

The New Amarin is on track to become a global, diversified cardiometabolic player as we implement a thoughtful and practical strategic plan designed to create value now.

About Amine
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our inception in scientific research, to our focus on clinical trials, to our commercial expansion, we are developing and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland and other countries in Europe, as well as trading partners and suppliers around the world. We are committed to advancing the scientific understanding of cardiovascular risk beyond traditional therapies and advancing the management of that risk.

Forward-Looking Statements
This press release contains forward-looking statements made under the US federal securities laws. These forward-looking statements are not promises or guarantees and involve significant risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the US Securities and Exchange Commission, including Amarin’s Annual Report on Form 10-K for the Year Ended 2021, and Amarin’s quarterly reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022 and its other filings. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise any information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of any significant transaction the company may enter into, such as any merger, acquisition, divestiture, joint venture or material agreement that Amarin may enter into, modify or terminate.

Amarin contact information

Investor Inquiries:

[email protected] (investor inquiries)

Media Inquiries:

[email protected] (media inquiries)

Or
Steve Frankel / Andi Rose / Tali Epstein
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449